| Similar Articles |
|---|
 |
The Motley Fool
May 30, 2008
Brian Orelli |
WuXi Woos Pharma Pharmaceutical outsourcing specialist WuXi PharmaTech proves that outsourcing to China isn't dead yet and neither are Chinese companies moving stateside.   |
The Motley Fool
November 12, 2009
Brian Orelli |
How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way. |
The Motley Fool
August 13, 2009
Brian Orelli |
WuXi: Making Money Both Ways Cost-cutting and revenue growth make pharma outsourcing specialist WuXi a looker for the year. |
The Motley Fool
June 25, 2008
Brian Orelli |
WuXi's Shortsighted Deal WuXi partners with Covance, but is it really a good long-term play? |
The Motley Fool
December 27, 2007
Brian Orelli |
Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there. |
The Motley Fool
August 13, 2007
Andrew R. Vaino |
Do You See What I WuXi? This Chinese biotech outsourcing firm recently went public and has lots of room to grow. |
The Motley Fool
October 1, 2008
Brian Orelli |
WuXi and Covance Call It Quits WuXi PharmaTech and Covance broke up yesterday - just three months after announcing they'd form an alliance to perform pre-clinical research for drug developers looking for research and development on the cheap. |
The Motley Fool
April 27, 2010
Brian Orelli |
Big Acquisition, Double-Digit Decline. Charles River Labs buys into China big time. But investors would rather have seen it stay home. |
The Motley Fool
August 1, 2008
Brian Orelli |
Recession Schmession, This Industry Is On Fire Contract research organizations do pre-clinical research and run clinical trials for drug developers on the cheap. With pharmaceutical companies cutting back on costs, CROs are in the perfect position to benefit. |
The Motley Fool
May 13, 2008
Brian Orelli |
Is Merck Keeping Its Enemies Close? The drugmaker strikes a deal with an Indian generic company. |
The Motley Fool
March 6, 2009
Brian Orelli |
For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations. |
The Motley Fool
December 28, 2007
Brian Orelli |
The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007. |
Pharmaceutical Executive
September 1, 2008
Zhu Shen |
Unleash the Dragon Concerns over quality? It's not stopping Big Pharma outsourcing and venture capital. |
Bio-IT World
October 14, 2004
Michael Greeley |
Go East Business is great in China, and the government is strongly encouraging the local biotech industry. |
The Motley Fool
December 7, 2010
Michael Kanellos |
Suntech Predicts 46 Percent Growth in Shipments in 2011 And a 30 percent growth in revenue with greater margins. Wall Street cautious but optimistic. |
The Motley Fool
October 11, 2007
Billy Fisher |
An IPO That Hit the Bull's-Eye Sirtris Pharmaceuticals presents promising drug data and is turning out to be one of the top-performing IPOs in the biotech/pharmaceutical field in 2007. |
